Key Takeaways
Sino Biopharmaceutical Ltd. (1177.HK) shares climbed 1.8 percent after its subsidiary, Chia Tai Tianqing, secured an exclusive 5.5-year deal with GlaxoSmithKline Plc to launch the breakthrough hepatitis B drug bepirovirsen in mainland China.
"Leveraging CTTQ’s leading hepatitis B franchise and network of more than 5,000 medical centres, the deal is expected to accelerate patient access," Sino Biopharmaceutical said in a statement, reinforcing its role as a preferred partner for multinational drugmakers.
Under the agreement, Chia Tai Tianqing will handle importation, distribution, hospital access, and all promotional activities, recognizing 100 percent of the sales revenue. GSK will continue as the Marketing Authorization Holder, responsible for regulatory affairs, quality control, and global medical strategy. Bepirovirsen, a first-in-class antisense oligonucleotide, has been granted Breakthrough Therapy status in China.
The partnership targets China's large, unmet public health need for chronic hepatitis B treatments and is poised to significantly bolster Sino Biopharm's liver disease pipeline and future revenue. The two companies will also explore further collaborations for other pipeline assets in markets outside of China.
The partnership solidifies CTTQ’s dominance in China's hepatitis B market and provides a significant new revenue stream. Investors will be watching for the successful launch and market uptake of bepirovirsen over the initial 5.5-year term, which may be extended by mutual agreement.
This article is for informational purposes only and does not constitute investment advice.
